Celldex Therapeutics, Inc. (NASDAQ:CLDX) Short Interest Update

Celldex Therapeutics, Inc. (NASDAQ:CLDXGet Free Report) was the recipient of a large drop in short interest during the month of March. As of March 15th, there was short interest totalling 5,900,000 shares, a drop of 8.0% from the February 29th total of 6,410,000 shares. Based on an average daily trading volume, of 927,100 shares, the short-interest ratio is presently 6.4 days.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the stock. Point72 Hong Kong Ltd lifted its stake in shares of Celldex Therapeutics by 57.9% in the 1st quarter. Point72 Hong Kong Ltd now owns 1,394 shares of the biopharmaceutical company’s stock valued at $47,000 after purchasing an additional 511 shares during the period. Allspring Global Investments Holdings LLC raised its stake in Celldex Therapeutics by 70.9% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 1,941 shares of the biopharmaceutical company’s stock worth $53,000 after buying an additional 805 shares during the period. Tower Research Capital LLC TRC raised its stake in Celldex Therapeutics by 604.9% during the 1st quarter. Tower Research Capital LLC TRC now owns 2,178 shares of the biopharmaceutical company’s stock worth $78,000 after buying an additional 1,869 shares during the period. Cubist Systematic Strategies LLC raised its stake in Celldex Therapeutics by 78.8% during the 1st quarter. Cubist Systematic Strategies LLC now owns 2,782 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 1,226 shares during the period. Finally, Strs Ohio raised its stake in Celldex Therapeutics by 92.9% during the 4th quarter. Strs Ohio now owns 2,700 shares of the biopharmaceutical company’s stock worth $107,000 after buying an additional 1,300 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have commented on CLDX. TD Cowen began coverage on Celldex Therapeutics in a research report on Wednesday, December 20th. They issued an “outperform” rating on the stock. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Finally, Guggenheim increased their price objective on Celldex Therapeutics from $72.00 to $90.00 and gave the company a “buy” rating in a research report on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, one has given a hold rating and four have given a buy rating to the stock. According to data from MarketBeat, Celldex Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $66.00.

Get Our Latest Analysis on CLDX

Celldex Therapeutics Price Performance

Shares of CLDX stock traded down $0.48 during trading hours on Tuesday, reaching $41.16. The company had a trading volume of 1,316,269 shares, compared to its average volume of 958,974. The company has a 50 day moving average of $41.33 and a 200 day moving average of $34.76. The firm has a market cap of $2.30 billion, a price-to-earnings ratio of -14.14 and a beta of 1.50. Celldex Therapeutics has a 1-year low of $22.11 and a 1-year high of $53.18.

Celldex Therapeutics (NASDAQ:CLDXGet Free Report) last posted its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.76) by $0.19. The company had revenue of $4.13 million for the quarter, compared to the consensus estimate of $1.20 million. Celldex Therapeutics had a negative return on equity of 41.06% and a negative net margin of 2,054.46%. As a group, sell-side analysts forecast that Celldex Therapeutics will post -2.93 EPS for the current fiscal year.

Celldex Therapeutics Company Profile

(Get Free Report)

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.

Read More

Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.